HK1212328A1 - Bicyclic aza compounds as muscarinic m1 receptor agonists m1 - Google Patents

Bicyclic aza compounds as muscarinic m1 receptor agonists m1

Info

Publication number
HK1212328A1
HK1212328A1 HK15112602.8A HK15112602A HK1212328A1 HK 1212328 A1 HK1212328 A1 HK 1212328A1 HK 15112602 A HK15112602 A HK 15112602A HK 1212328 A1 HK1212328 A1 HK 1212328A1
Authority
HK
Hong Kong
Prior art keywords
muscarinic
receptor agonists
aza compounds
bicyclic aza
bicyclic
Prior art date
Application number
HK15112602.8A
Other languages
English (en)
Chinese (zh)
Inventor
Giles Albert Brown
Julie Elaine Cansfield
Miles Stuart Congreve
Mark Pickworth
Benjamin Gerald Tehan
Original Assignee
Heptares Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heptares Therapeutics Ltd filed Critical Heptares Therapeutics Ltd
Publication of HK1212328A1 publication Critical patent/HK1212328A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002Heterocyclic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK15112602.8A 2012-09-18 2015-12-22 Bicyclic aza compounds as muscarinic m1 receptor agonists m1 HK1212328A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261702330P 2012-09-18 2012-09-18
US201361823606P 2013-05-15 2013-05-15
PCT/GB2013/052442 WO2014045031A1 (fr) 2012-09-18 2013-09-18 Composés aza bicycliques utilisés comme agonistes du récepteur muscarinique m1

Publications (1)

Publication Number Publication Date
HK1212328A1 true HK1212328A1 (en) 2016-06-10

Family

ID=49237505

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15112602.8A HK1212328A1 (en) 2012-09-18 2015-12-22 Bicyclic aza compounds as muscarinic m1 receptor agonists m1

Country Status (12)

Country Link
US (4) US9266857B2 (fr)
EP (1) EP2897948B1 (fr)
JP (2) JP6204476B2 (fr)
CN (2) CN104640851B (fr)
AU (2) AU2013319989C1 (fr)
BR (1) BR112015006029B1 (fr)
CA (1) CA2883210C (fr)
DK (1) DK2897948T3 (fr)
ES (1) ES2602039T3 (fr)
HK (1) HK1212328A1 (fr)
SG (1) SG11201501620QA (fr)
WO (1) WO2014045031A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE033114T2 (en) * 2011-11-18 2017-11-28 Heptares Therapeutics Ltd Muscarin M1 receptor agonists
CN104640851B (zh) * 2012-09-18 2017-05-31 赫普泰雅治疗有限公司 作为毒蕈碱的m1受体激动剂的二环氮杂化合物
NZ723103A (en) 2014-02-06 2022-09-30 Heptares Therapeutics Ltd Bicyclic aza compounds as muscarinic m1 receptor and/or m4 receptor agonists
GB201404922D0 (en) 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201504675D0 (en) * 2015-03-19 2015-05-06 Heptares Therapeutics Ltd Pharmaceutical compounds
US10526287B2 (en) 2015-04-23 2020-01-07 Constellation Pharmaceuticals, Inc. LSD1 inhibitors and uses thereof
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201513740D0 (en) * 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonist
GB201513742D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
JP6639651B2 (ja) * 2015-09-04 2020-02-05 ヤンセン ファーマシューティカ エヌ.ベー. 疼痛のための治療化合物及びその合成
GB201519352D0 (en) * 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
WO2017210545A1 (fr) 2016-06-02 2017-12-07 Cadent Therapeutics, Inc. Modulateurs des canaux potassiques
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
CN109863137B (zh) 2016-10-26 2022-12-16 星座制药公司 Lsd1抑制剂及其医学用途
JP6997197B2 (ja) 2017-01-23 2022-01-17 カデント セラピューティクス,インコーポレーテッド カリウムチャネルモジュレーター
US11065235B2 (en) 2017-05-19 2021-07-20 Council Of Scientific & Industrial Research Substituted methanopyrido [2, 1-a] isoindolones as mAChR modulators for treating various associated pathophysiological conditions and process for preparation thereof
GB201709652D0 (en) 2017-06-16 2017-08-02 Heptares Therapeutics Ltd Pharmaceutical compounds
TW201922758A (zh) 2017-10-24 2019-06-16 美商歐樂根公司 烯胺及烯胺的非鏡像選擇性還原
CN111565718A (zh) 2017-10-31 2020-08-21 范德比尔特大学 毒蕈碱性乙酰胆碱受体m4的拮抗剂
WO2019126559A1 (fr) 2017-12-20 2019-06-27 Vanderbilt University Antagonistes du récepteur muscarinique de l'acétylcholine m4
GB201810245D0 (en) * 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201810239D0 (en) * 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
US12054487B2 (en) 2018-09-04 2024-08-06 Contineum Therapeutics, Inc. Muscarinic acetylcholine M1 receptor antagonists
AU2019366312A1 (en) 2018-10-22 2021-05-20 Novartis Ag Crystalline forms of potassium channel modulators
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds
UY38906A (es) * 2019-10-09 2021-05-31 Novartis Ag Compuestos 2- derivados de azaspiro[3,4]octano como agonistas de m4 y composiciones de los mismos
AU2020364186B2 (en) 2019-10-09 2023-11-30 Novartis Ag 5-oxa-2-azaspiro(3.4)octane derivatives as M4 agonists
KR20230170937A (ko) * 2021-04-13 2023-12-19 파이프라인 테라퓨틱스, 아이엔씨. 무스카린성 아세틸콜린 m1 수용체 길항제의 결정질 화합물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999032479A1 (fr) * 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Derives de phtalamidepiperidine, de phtalamidepyrrolidine, et de phtalamide-azepine, leur preparation, et leur utilisation comme agonistes(antagonistes) des recepteurs muscariniques
US7524852B2 (en) * 2002-06-07 2009-04-28 Kyowa Hakko Kogyo Co., Ltd. Bicyclic pyrimidine derivatives
MXPA06013842A (es) * 2004-05-28 2007-03-01 Vertex Pharma Moduladores de receptores muscarinicos.
EP1863490A2 (fr) * 2005-03-28 2007-12-12 Vertex Pharmaceuticals Incorporated Modulateurs muscariniques
US7858635B2 (en) 2005-12-22 2010-12-28 Vertex Pharmaceuticals Incorporated Spiro compounds as modulators of muscarinic receptors
TW200815405A (en) * 2006-06-09 2008-04-01 Astrazeneca Ab Novel compounds
US8119661B2 (en) * 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
US20090221567A1 (en) * 2008-02-28 2009-09-03 Astrazeneca Ab Muscarinic receptor agonists, compositions, methods of treatment thereof, and processes for preparation thereof 177
WO2011112825A2 (fr) * 2010-03-10 2011-09-15 Vanderbilt University Analogues d'hétérocyclyl-azabicyclo[3.2.1]octane comme agonistes sélectifs de m1 et leurs procédés de fabrication et d'utilisation
HUE033114T2 (en) 2011-11-18 2017-11-28 Heptares Therapeutics Ltd Muscarin M1 receptor agonists
CN104640851B (zh) * 2012-09-18 2017-05-31 赫普泰雅治疗有限公司 作为毒蕈碱的m1受体激动剂的二环氮杂化合物

Also Published As

Publication number Publication date
ES2602039T3 (es) 2017-02-17
CN107098899B (zh) 2019-09-06
US10259802B2 (en) 2019-04-16
AU2017204256A1 (en) 2017-07-13
WO2014045031A1 (fr) 2014-03-27
CA2883210C (fr) 2021-06-15
AU2013319989A1 (en) 2015-03-12
BR112015006029A2 (pt) 2017-07-04
US9669013B2 (en) 2017-06-06
AU2013319989B2 (en) 2017-03-30
JP2015528489A (ja) 2015-09-28
US9975890B2 (en) 2018-05-22
DK2897948T3 (en) 2016-12-05
US20150232443A1 (en) 2015-08-20
US20180258085A1 (en) 2018-09-13
AU2013319989C1 (en) 2017-08-17
JP6438091B2 (ja) 2018-12-12
US9266857B2 (en) 2016-02-23
CA2883210A1 (fr) 2014-03-27
CN104640851A (zh) 2015-05-20
BR112015006029B1 (pt) 2022-01-25
CN104640851B (zh) 2017-05-31
JP2018021057A (ja) 2018-02-08
US20170247369A1 (en) 2017-08-31
EP2897948A1 (fr) 2015-07-29
EP2897948B1 (fr) 2016-08-31
JP6204476B2 (ja) 2017-09-27
SG11201501620QA (en) 2015-04-29
CN107098899A (zh) 2017-08-29
US20160128996A1 (en) 2016-05-12
AU2017204256B2 (en) 2018-10-18

Similar Documents

Publication Publication Date Title
HK1212328A1 (en) Bicyclic aza compounds as muscarinic m1 receptor agonists m1
HRP20181499T1 (hr) Bičiklički aza spojevi kao agonisti muskarinskih m1 receptora
HK1206722A1 (en) New bicyclic derivatives
HK1212984A1 (zh) 咪唑並吡啶化合物
HK1201737A1 (en) Muscarinic m1 receptor agonists
HK1252279A1 (zh) 5- ht3受體拮抗劑
IL232570B (en) Bicyclic derivatives of dihydroisoquinoline-1-one
EP2840076A4 (fr) Composé bicyclique
EP2670746A4 (fr) Composés hétéroaryles bicycliques en tant qu&#39;agonistes du récepteur gpr119
HK1206340A1 (en) New bicyclic thiophenylamide compounds
HK1205738A1 (en) Bicyclic substituted pyrimidine compounds
EP2874621A4 (fr) Antagonistes des récepteurs aux minéralocorticoïdes
GB201502644D0 (en) Bicyclic aza compounds as muscarinic m1 receptor agonists
EP2864332A4 (fr) Composés imidazo bicycliques imminium en tant qu&#39;agents anti-tumoraux
GB201216373D0 (en) Appetite-suppressant composition